Funded Biotechnology Startups in Charlottesville
Biotechnology funding in Charlottesville shows a wide spread in disclosed round sizes: the largest disclosed round is Contraline’s $93M (2026-06-02), which…
Biotechnology funding in Charlottesville shows a wide spread in disclosed round sizes: the largest disclosed round is Contraline’s $93M (2026-06-02), which sits well above the next-largest disclosed amounts—Adial Pharmaceuticals at $32M (2026-06-11) and Rivus Pharmaceuticals at $132M (2022-09-22). Overall, disclosed amounts cluster in the $150K–$32M range across multiple years, while only a few rows fall near or above the tens of millions (e.g., Adial Pharmaceuticals $32M in 2026 and HemoShear Therapeutics $4M in 2023).
Timing also clusters: 3 of the 11 rows are dated in June 2026 (Adial Pharmaceuticals 2026-06-11, Contraline 2026-06-02, and Avant Genomics 2026-05-13 is adjacent), and the oldest entry shown is Transfoam’s $20K grant (2022-05-12). Stage and disclosure are mixed, with 5 of 11 rows marked “Series Unknown” (Adial Pharmaceuticals 2026-06-11; HemoShear Therapeutics 2023-11-14; CvilleBioHub 2023-08-14; AMPEL BioSolutions 2023-07-06; PS Fertility 2023-06-26) and 1 row explicitly “undisclosed” (PS Fertility, 2023-06-26).
Most recent rounds
11 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Charlottesville biotech list, and how does it compare to the rest of the disclosed amounts?
The largest disclosed amount is Rivus Pharmaceuticals’ $132M round on 2022-09-22. That figure dwarfs the next-largest disclosed amounts in the table—Contraline’s $93M (2026-06-02) and Adial Pharmaceuticals’ $32M (2026-06-11).
Do multiple rounds cluster in a narrow recent date window, or are they spread evenly across years?
They cluster near the top of the date range: three of the 11 entries are in June 2026 (Adial Pharmaceuticals 2026-06-11 for $32M; Contraline 2026-06-02 for $93M; and a nearby May 2026 Seed for Avant Genomics 2026-05-13 for $3M). Outside that, the remaining rounds are concentrated in 2022–2023, with the oldest row dated 2022-05-12 (Transfoam, $20K).
Which entries are “Series Unknown” or “undisclosed,” and does that dominate the stage pattern?
Five of the 11 rows are labeled “Series Unknown” (Adial Pharmaceuticals $32M on 2026-06-11; HemoShear Therapeutics $4M on 2023-11-14; CvilleBioHub $200K on 2023-08-14; AMPEL BioSolutions $2M on 2023-07-06; PS Fertility on 2023-06-26). In addition, PS Fertility’s 2023-06-26 amount is explicitly “undisclosed,” creating a disclosure gap even within the “Series Unknown” group.
Are there notable outliers on the low end of disclosed funding amounts?
Yes. The smallest disclosed amount is Transfoam’s $20K grant on 2022-05-12, which sits below other low disclosed rounds like CvilleBioHub’s $200K (2023-08-14) and Ourobio’s $150K pre-seed (2022-08-05).
How does the stage mix break down between early-stage labels (Seed/Pre-Seed) and named later stages (e.g., Series B)?
Early-stage labels appear repeatedly: Avant Genomics is Seed ($3M on 2026-05-13), Atelerix Life Sciences is Seed ($650K on 2022-10-01), and Ourobio is Pre-Seed ($150K on 2022-08-05). Named later-stage labels are fewer but visible—Contraline is Series B ($93M on 2026-06-02) and Rivus Pharmaceuticals is Series B ($132M on 2022-09-22).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.